Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of diseases. The company's commercialized medicines and product candidates in development are designed to assist patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and rare diseases. The company's products include: EYLEA (aflibercept) injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema; and Dupixent (dupilumab) injection, which is used for the treatment of adult patients with atopic dermatitis.
  • TickerREGN
  • ISINUS75886F1075
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
REGN Regeneron Pharm... (Health Care)

Regeneron Pharmaceuticals, Inc.: Update to credit analysis - strong pe...

Our credit view of this issuer reflects its strong R&D capabilities and it long track record of very low financial leverage, offset by approaching biosimilar competition for Eylea.

REGN Regeneron Pharm... (Health Care)

Regeneron Pharmaceuticals Inc: 1 director

A director at Regeneron Pharmaceuticals Inc sold 80,000 shares at 538.902USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. Th...

REGN Regeneron Pharm... (Health Care)

REGENERON PHARMA sees a downgrade to Neutral on account of less fundam...

The independent financial analyst theScreener just lowered the general evaluation of REGENERON PHARMA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date September 25, 2020, the closing price was USD 574.06 and its target price was estimated at USD 481.29.

Valens Research
  • Valens Research
REGN Regeneron Pharm... (Health Care)

REGN - Embedded Expectations Analysis - 2020 09 25

Regeneron Pharmaceuticals, Inc. (REGN:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with an 11.8x Uniform P/E, implying bearish expectations for the firm. Moreover, management may be concerned about potential the side effects of Fasinumab, EYLEA, and their oncology business Specifically, management may lack confidence in their ability to reduce non-GAAP expenses, explore new combinations of drugs that could benefit a wide variety of cancer patients, and improve their oncology business. Management may also have concerns about the sustainability of d...

Valens Research
  • Valens Research
REGN Regeneron Pharm... (Health Care)

REGN - Embedded Expectations Analysis - 2020 01 22

 Regeneron Pharmaceuticals, Inc. (REGN:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 10.7x Uniform P/E, implying bearish expectations for the firm. Moreover, management may be concerned about DUPIXENT growth opportunities, revenue growth, and cost management  Specifically, management may lack confidence in their ability to sustain DUPIXENT new-to-brand prescription growth, and they may be exaggerating the growth opportunities for DUPIXENT among patients with chronic rhinosinusitis, asthma, or atopic dermatitis. Moreover, they may lack c...

REGN Regeneron Pharm... (Health Care)

Regeneron Pharmaceuticals, Inc.: Update to credit analysis - strong pe...

Our credit view of this issuer reflects its strong R&D capabilities and it long track record of very low financial leverage, offset by approaching biosimilar competition for Eylea.

REGN Regeneron Pharm... (Health Care)

Regeneron Pharmaceuticals Inc: 1 director

A director at Regeneron Pharmaceuticals Inc sold 80,000 shares at 538.902USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. Th...

REGN Regeneron Pharm... (Health Care)

REGENERON PHARMA sees a downgrade to Neutral on account of less fundam...

The independent financial analyst theScreener just lowered the general evaluation of REGENERON PHARMA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date September 25, 2020, the closing price was USD 574.06 and its target price was estimated at USD 481.29.

Valens Research
  • Valens Research
REGN Regeneron Pharm... (Health Care)

REGN - Embedded Expectations Analysis - 2020 09 25

Regeneron Pharmaceuticals, Inc. (REGN:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with an 11.8x Uniform P/E, implying bearish expectations for the firm. Moreover, management may be concerned about potential the side effects of Fasinumab, EYLEA, and their oncology business Specifically, management may lack confidence in their ability to reduce non-GAAP expenses, explore new combinations of drugs that could benefit a wide variety of cancer patients, and improve their oncology business. Management may also have concerns about the sustainability of d...

Valens Research
  • Valens Research
REGN Regeneron Pharm... (Health Care)

REGN - Embedded Expectations Analysis - 2020 01 22

 Regeneron Pharmaceuticals, Inc. (REGN:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 10.7x Uniform P/E, implying bearish expectations for the firm. Moreover, management may be concerned about DUPIXENT growth opportunities, revenue growth, and cost management  Specifically, management may lack confidence in their ability to sustain DUPIXENT new-to-brand prescription growth, and they may be exaggerating the growth opportunities for DUPIXENT among patients with chronic rhinosinusitis, asthma, or atopic dermatitis. Moreover, they may lack c...

REGN Regeneron Pharm... (Health Care)

Regeneron Pharmaceuticals, Inc.: Update to credit analysis - strong pe...

Our credit view of this issuer reflects its strong R&D capabilities and it long track record of very low financial leverage, offset by approaching biosimilar competition for Eylea.

REGN Regeneron Pharm... (Health Care)

Regeneron Pharmaceuticals Inc: 1 director

A director at Regeneron Pharmaceuticals Inc sold 80,000 shares at 538.902USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. Th...

REGN Regeneron Pharm... (Health Care)

REGENERON PHARMA sees a downgrade to Neutral on account of less fundam...

The independent financial analyst theScreener just lowered the general evaluation of REGENERON PHARMA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date September 25, 2020, the closing price was USD 574.06 and its target price was estimated at USD 481.29.

Valens Research
  • Valens Research
REGN Regeneron Pharm... (Health Care)

REGN - Embedded Expectations Analysis - 2020 09 25

Regeneron Pharmaceuticals, Inc. (REGN:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with an 11.8x Uniform P/E, implying bearish expectations for the firm. Moreover, management may be concerned about potential the side effects of Fasinumab, EYLEA, and their oncology business Specifically, management may lack confidence in their ability to reduce non-GAAP expenses, explore new combinations of drugs that could benefit a wide variety of cancer patients, and improve their oncology business. Management may also have concerns about the sustainability of d...

Valens Research
  • Valens Research
REGN Regeneron Pharm... (Health Care)

REGN - Embedded Expectations Analysis - 2020 01 22

 Regeneron Pharmaceuticals, Inc. (REGN:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 10.7x Uniform P/E, implying bearish expectations for the firm. Moreover, management may be concerned about DUPIXENT growth opportunities, revenue growth, and cost management  Specifically, management may lack confidence in their ability to sustain DUPIXENT new-to-brand prescription growth, and they may be exaggerating the growth opportunities for DUPIXENT among patients with chronic rhinosinusitis, asthma, or atopic dermatitis. Moreover, they may lack c...

REGN Regeneron Pharm... (Health Care)

Regeneron Pharmaceuticals, Inc.: Update to credit analysis - strong pe...

Our credit view of this issuer reflects its strong R&D capabilities and it long track record of very low financial leverage, offset by approaching biosimilar competition for Eylea.

REGN Regeneron Pharm... (Health Care)

Regeneron Pharmaceuticals Inc: 1 director

A director at Regeneron Pharmaceuticals Inc sold 80,000 shares at 538.902USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. Th...

REGN Regeneron Pharm... (Health Care)

REGENERON PHARMA sees a downgrade to Neutral on account of less fundam...

The independent financial analyst theScreener just lowered the general evaluation of REGENERON PHARMA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date September 25, 2020, the closing price was USD 574.06 and its target price was estimated at USD 481.29.

Valens Research
  • Valens Research
REGN Regeneron Pharm... (Health Care)

REGN - Embedded Expectations Analysis - 2020 09 25

Regeneron Pharmaceuticals, Inc. (REGN:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with an 11.8x Uniform P/E, implying bearish expectations for the firm. Moreover, management may be concerned about potential the side effects of Fasinumab, EYLEA, and their oncology business Specifically, management may lack confidence in their ability to reduce non-GAAP expenses, explore new combinations of drugs that could benefit a wide variety of cancer patients, and improve their oncology business. Management may also have concerns about the sustainability of d...

Valens Research
  • Valens Research
REGN Regeneron Pharm... (Health Care)

REGN - Embedded Expectations Analysis - 2020 01 22

 Regeneron Pharmaceuticals, Inc. (REGN:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 10.7x Uniform P/E, implying bearish expectations for the firm. Moreover, management may be concerned about DUPIXENT growth opportunities, revenue growth, and cost management  Specifically, management may lack confidence in their ability to sustain DUPIXENT new-to-brand prescription growth, and they may be exaggerating the growth opportunities for DUPIXENT among patients with chronic rhinosinusitis, asthma, or atopic dermatitis. Moreover, they may lack c...

REGN Regeneron Pharm... (Health Care)

Regeneron Pharmaceuticals, Inc.: Update to credit analysis - strong pe...

Our credit view of this issuer reflects its strong R&D capabilities and it long track record of very low financial leverage, offset by approaching biosimilar competition for Eylea.

REGN Regeneron Pharm... (Health Care)

Regeneron Pharmaceuticals Inc: 1 director

A director at Regeneron Pharmaceuticals Inc sold 80,000 shares at 538.902USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. Th...

REGN Regeneron Pharm... (Health Care)

REGENERON PHARMA sees a downgrade to Neutral on account of less fundam...

The independent financial analyst theScreener just lowered the general evaluation of REGENERON PHARMA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date September 25, 2020, the closing price was USD 574.06 and its target price was estimated at USD 481.29.

Valens Research
  • Valens Research
REGN Regeneron Pharm... (Health Care)

REGN - Embedded Expectations Analysis - 2020 09 25

Regeneron Pharmaceuticals, Inc. (REGN:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with an 11.8x Uniform P/E, implying bearish expectations for the firm. Moreover, management may be concerned about potential the side effects of Fasinumab, EYLEA, and their oncology business Specifically, management may lack confidence in their ability to reduce non-GAAP expenses, explore new combinations of drugs that could benefit a wide variety of cancer patients, and improve their oncology business. Management may also have concerns about the sustainability of d...

Valens Research
  • Valens Research
REGN Regeneron Pharm... (Health Care)

REGN - Embedded Expectations Analysis - 2020 01 22

 Regeneron Pharmaceuticals, Inc. (REGN:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 10.7x Uniform P/E, implying bearish expectations for the firm. Moreover, management may be concerned about DUPIXENT growth opportunities, revenue growth, and cost management  Specifically, management may lack confidence in their ability to sustain DUPIXENT new-to-brand prescription growth, and they may be exaggerating the growth opportunities for DUPIXENT among patients with chronic rhinosinusitis, asthma, or atopic dermatitis. Moreover, they may lack c...

REGN Regeneron Pharm... (Health Care)

Regeneron Pharmaceuticals, Inc.: Update to credit analysis - strong pe...

Our credit view of this issuer reflects its strong R&D capabilities and it long track record of very low financial leverage, offset by approaching biosimilar competition for Eylea.

REGN Regeneron Pharm... (Health Care)

Regeneron Pharmaceuticals Inc: 1 director

A director at Regeneron Pharmaceuticals Inc sold 80,000 shares at 538.902USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. Th...

REGN Regeneron Pharm... (Health Care)

REGENERON PHARMA sees a downgrade to Neutral on account of less fundam...

The independent financial analyst theScreener just lowered the general evaluation of REGENERON PHARMA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date September 25, 2020, the closing price was USD 574.06 and its target price was estimated at USD 481.29.

Valens Research
  • Valens Research
REGN Regeneron Pharm... (Health Care)

REGN - Embedded Expectations Analysis - 2020 09 25

Regeneron Pharmaceuticals, Inc. (REGN:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with an 11.8x Uniform P/E, implying bearish expectations for the firm. Moreover, management may be concerned about potential the side effects of Fasinumab, EYLEA, and their oncology business Specifically, management may lack confidence in their ability to reduce non-GAAP expenses, explore new combinations of drugs that could benefit a wide variety of cancer patients, and improve their oncology business. Management may also have concerns about the sustainability of d...

Valens Research
  • Valens Research
REGN Regeneron Pharm... (Health Care)

REGN - Embedded Expectations Analysis - 2020 01 22

 Regeneron Pharmaceuticals, Inc. (REGN:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 10.7x Uniform P/E, implying bearish expectations for the firm. Moreover, management may be concerned about DUPIXENT growth opportunities, revenue growth, and cost management  Specifically, management may lack confidence in their ability to sustain DUPIXENT new-to-brand prescription growth, and they may be exaggerating the growth opportunities for DUPIXENT among patients with chronic rhinosinusitis, asthma, or atopic dermatitis. Moreover, they may lack c...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch